49
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Reducing the trigger dose of recombinant hCG in high-responder patients attending an assisted reproductive technology program: an observational study

, &
Pages 1691-1694 | Published online: 18 May 2016

References

  • LudwigMDoodyKJDoodyKMUse of recombinant human chorionic gonadotropin in ovulation inductionFertil Steril20037951051105912738494
  • HumaidanPQuartaroloJPapanikolaouEGPreventing ovarian hyperstimulation syndrome: guidance for the clinicianFertil Steril201094238940020416867
  • NavotDBerghPALauferNOvarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatmentFertil Steril19925822492611633889
  • KlemettiRSevónTGisslerMHemminkiEComplications of IVF and ovulation inductionHum Reprod200520123293330016126753
  • GolanARon-elRHermanASofferYWeinraubZCaspiEOvarian hyperstimulation syndrome: an update reviewObstet Gynecol Surv19894464304402660037
  • ShapiroBSDaneshmandSTGarnerFCAguirreMRossRMorrisSEffects of ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilizationFertil Steril2005841939816009163
  • KashyapSParkerKCedarsMIRosenwaksZOvarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger doseSemin Reprod Med201028647548521082506
  • TsoumpouIMugluJGelbayaTANardoLGSymposium: update on prediction and management of OHSS. Optimal dose of HCG for final oocyte maturation in IVF cycles: absence of evidence?Reprod Biomed Online2009191525819573290
  • Al-InanyHAboulgharMAMansourRTProctorMRecombinant versus urinary gonadotrophins for triggering ovulation in assisted conceptionHum Reprod20052082061207316024539
  • European Medicines Agency Science Medicines Health [webpage on the Internet]Ovitrelle Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000320/human_med_000964.jspAccessed April 6, 2016
  • NargundGHutchisonLScaramuzziRCampbellSLow-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cyclesReprod Biomed Online200714668268517579978
  • ChenXChenSLHeYXYeDSMinimum dose of hCG to trigger final oocyte maturation and prevent OHSS in a long GnRHa protocolJ Huazhong Univ Sci Technolog Med Sci201333113313623392722
  • AbdallaHIAh-MoyeMBrinsdenPHoweDLOkonofuaFCraftIThe effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization programFertil Steril19874869589633119376
  • KolibianakisEMPapanikolaouEGTournayeHCamusMVan SteirteghemACDevroeyPTriggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormoneFertil Steril20078851382138817445806
  • SchmidtDWMaierDBNulsenJCBenadivaCAReducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilizationFertil Steril200482484184615482757